🚀 We’ve just launched the NEW ESC website: ✔ Faster, smarter navigation ✔ AI-powered search ✔ New topic pages & community highlights ✔ ESC Chatbot for quick answers Enjoy exploring and access content that matters👉 escardio.org/ #ESCardioEd #cardiology #CVD

What an unforgettable #ESCCongress 2025! The worldwide CV community came together here in Madrid to share science, ideas, and inspiration. We were honoured by the presence of His Majesty King Felipe VI of Spain and the Spanish Minister of Health, adding to this historic moment. With record numbers of participants, the atmosphere was simply fantastic, all set against the vibrant backdrop of Madrid. Thank you for being part of this extraordinary week. See you next year! 🤗

#ESCCongressVisuals from Hot Line 5👇 DANCANVAS 2 attempts to reduce social inequality in cardiovascular health by performing an interventional screening trial on how best to decrease cardiovascular disease amongst individuals of low social status. 👇 PREVENT-MINS is a multicentre, superiority randomized controlled trial of ivabradine versus placebo. The primary objective is to determine the impact of ivabradine on the risk of MI in patients 30 days after noncardiac surgery 👇 The ABC-AF study evaluates whether a personalized treatment recommendation strategy-guided by the biomarkers improves outcomes in AF. How generalizable is this study? 👇 Patients with acute VTE in the setting of transient provoking factors are treated with short-term anticoagulation. However, the risk of recurrence may increase if there are enduring risk factors. Will patients receiving extended treatment of apixaban reduce recurrence rates? HI-PRO is a single-center, double-blind randomized trial that answers this question. 👇 #ESCCongress #ESCCongressVisuals